Biology Reference
In-Depth Information
Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL,
Wang Y, Kass DA (2005b) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents
and reverses cardiac hypertrophy. Nat Med 11:214-222
Taniguchi Y, Tonai-Kachi H, Shinjo K (2006) Zaprinast, a well-known cyclic guanosine mono-
phosphate-specific phosphodiesterase inhibitor,
is an agonist
for GPR35. FEBS Lett
580:5003-5008
Tasken KA, Collas P, Kemmner WA, Witczak O, Conti M, Tasken K (2001) Phosphodiesterase
4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J Biol Chem
276:21999-22002
Tenor H, Hatzelmann A, Beume R, Lahu G, Zech K, Bethke TD (2011) Pharmacology, clinical
efficacy and tolerability of PDE4 inhibitors: Impact of human pharmacokinetics. Francis SH,
Conti M, HouslayMD (eds) Phosphodiesterases as drug targets. Springer, Heidelberg
Thomas MK, Francis SH, Beebe SJ, Gettys TW, Corbin JD (1992) Partial mapping of cyclic
nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic
nucleotide analogues. Adv Second Messenger Phosphoprotein Res 25:45-53
Thompson WJ (1991) Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and
function. Pharmacol Ther 51:13-33
Tian G, Rocque WJ, Wiseman JS, Thompson IZ, Holmes WD, Domanico PL, Stafford JA,
Feldman PL, Luther MA (1998) Dual inhibition of human type 4 phosphodiesterase isostates
by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrro-
lidinecarboxylate. Biochemistry 37:6894-6904
Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G (2008) Vardenafil, but
not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary
artery and human washed platelets. Br J Pharmacol 154:787-796
Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am
J Respir Crit Care Med 157:351-370
Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R (2002) Pharmacological profile of a novel
phosphodiesterase 4 inhibitor, 4-(8-benzo[1, 2, 5]oxadiazol-5-yl-[1, 7]naphthyridin-6-yl)-benzoic
acid (NVP-ABE171), a 1, 7-naphthyridine derivative, with anti-inflammatory activities.
J Pharmacol Exp Ther 301:241-248
Turko IV, Ballard SA, Francis SH, Corbin JD (1999) Inhibition of cyclic GMP-binding
cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol
Pharmacol 56:124-130
Uhler MD (1993) Cloning and expression of a novel cyclic GMP-dependent protein kinase from
mouse brain. J Biol Chem 268:13586-13591
Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD, Francis SH, Kukreja RC,
Movsesian MA (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and
failing human and mouse myocardium. J Pharmacol Exp Ther 330:884-891
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson
F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S
(2009) Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of
Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quino-
line (PF-2545920) for the Treatment of Schizophrenia (dagger) dagger Coordinates of the
PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1
(3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). J Med Chem 52:5188
Walseth TF, Gander JE, Eide SJ, Krick TP, Goldberg ND (1983) 18O labeling of adenine
nucleotide alpha-phosphoryls in platelets. Contribution by phosphodiesterase-catalyzed hydro-
lysis of cAMP. J Biol Chem 258:1544-1558
Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM (1997) Expression,
purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) sub-
types A, B, C, and D. Biochem Biophys Res Commun 234:320-324
Wang H, Liu Y, Chen Y, Robinson H, Ke H (2005) Multiple elements jointly determine inhibitor
selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949-30955
